Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCLByMatthew S. McKinney, MDJuly 11th 2022Matthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.